Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Immunoglobulin G pegylated - Mitsubishi Tanabe Pharma

Drug Profile

Immunoglobulin G pegylated - Mitsubishi Tanabe Pharma

Alternative Names: GB-0998; Human immunoglobulin G - Mitsubishi Tanabe Pharma; Immunoglobulin intravenous - Mitsubishi Tanabe Pharma; Intravenous immunoglobulin - Mitsubishi Tanabe Pharma; Kenketsu Venoglobulin-IH; Polyethylene glycol treated human normal immunoglobulin; Venoglobulin IH

Latest Information Update: 15 Feb 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Mitsubishi Pharma Corporation
  • Developer Japan Blood Products Organization; Mitsubishi Tanabe Pharma Corporation
  • Class Immunoglobulin isotypes
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Myasthenia gravis; Dermatomyositis
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Agammaglobulinaemia; Bacterial infections; Bronchitis; Dermatomyositis; Myasthenia gravis; Otitis; Pneumonia; Polymyositis
  • No development reported Guillain-Barre syndrome
  • Discontinued Immunodeficiency disorders; Systemic scleroderma

Most Recent Events

  • 15 Feb 2019 No development reported - Phase-III for Guillain-Barre syndrome in Japan (IV)
  • 29 Oct 2012 Discontinued - Phase-III for Systemic scleroderma in Japan (IV)
  • 29 Oct 2012 Discontinued - Preregistration for Immunodeficiency disorders in Japan (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top